Cabergoline treatment in men with psychogenic erectile dysfunction: A randomized, double-blind, placebo-controlled study

International Journal of Impotence Research

Volumn 19, Issue 1, 2007, Pages 104-107

  Nickel, M ^a,b,e   Moleda, D ^a   Loew, T ^c   Rother, W ^a   Gil, F Pedrosa ^d  

^a Inntalklinik   (Germany)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e Psychosomatics   (Germany)

Author keywords

Cabergoline; Libido; Prolactin; Psychogenic erectile dysfunction; Quality of life; Testosterone

Indexed keywords

CABERGOLINE; FOLLITROPIN; LUTEINIZING HORMONE; PLACEBO; PROLACTIN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; FOLLITROPIN BLOOD LEVEL; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MALE; MOLECULAR INTERACTION; NAUSEA; ORGASM; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOGENIC ERECTILE DYSFUNCTION; PSYCHOGENIC IMPOTENCE; PSYCHOLOGIC TEST; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SEXUAL SATISFACTION; SEXUALITY; STATISTICAL SIGNIFICANCE; TESTOSTERONE BLOOD LEVEL;

ADULT; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; ERGOLINES; FOLLICLE STIMULATING HORMONE; HUMANS; IMPOTENCE; LIBIDO; LUTEINIZING HORMONE; MALE; MIDDLE AGED; ORGASM; PATIENT SATISFACTION; PLACEBOS; PROLACTIN; TESTOSTERONE;

EID: 33846095542     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901483     Document Type: Article

References (13)

1. Cavallero R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 2004; 65: 187-190.
2. Krueger THC, Haake P, Haverkamp J, Kramer M, Exton MS, Saller B et al. Effects of acute prolactin manipulation on sexual drive and function in males. J Endocrinol 2003; 179: 357-365.
3. Wittstock M, Benecke R, Dressler D. Cabergoline can increase penile erections and libido. Neurology 2002; 58: 831.
4. De Rosa M, Zarrilli S, Vitale G, Di Somma C, Orio F, Tauchmanova L et al. Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab 2004; 89: 621-625.
5. Wiltink J, Hauck EW, Phadayanon M, Weidner W, Beutel ME. Validation of the German version of the International Index of Erectile Function (IIEF) in patients with erectile dysfunction, Peyronie's disease and controls. Int J Impot Res 2003; 15: 192-197.
6. Muellner M. Evidence based medicine. Springer: Wien, New York, 2002.
7. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1976; 6: 278-296.
8. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50-55.
9. Schulz P, Scholtz W, Becker P. Trier Inventory for the Assessment of Chronic Stress. Goettingen: Hogrefe, 2004.
10. Mac Donagh R, Ewings P, Porter T. The effect of erectile dysfunction on quality of life: psychometric testing of a new quality of life measure for patients with erectile dysfunction. J Urol 2002; 167: 212-217.
11. Glick HA, McCarron TJ, Althof SE, Corty EW, Willke RJ. Construction of scales for the Center for Marital and Sexual Health (CMASH). Sexual Functionning Questionnaire. J Sex Marital Ther 1997; 23: 103-117.
12. De Rosa M, Zarrilli S, Di Sarno A, Milano N, Gaccione M, Boggia B et al. Hyperprolactinemia in men. Endocrine 2003; 20: 75-82.
13. Hull EM, Lorrain DS, Du J, Matuszewich L, Lumley LA, Putnam SK et al. Hormone-neurotrasmitter interactions in the control of sexual behavior. Behav Brain Res 1999; 105: 105-116.